When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AIMT - Aimmune Proves Its Worth With Latest FDA Approval; Other Candidates Left To Advance
Aimmune Therapeutics Inc.
Aimmune (AIMT) announced that it had received FDA approval for its peanut allergy drug known as PALFORZIA. It was approved to treat patients with peanut allergy. The goal of its drug is to prevent any issues that may arise from allergic reactions including anaphylaxis. This FDA approval is a first of its kind for peanut allergy. In addition, the biotech already has other target indications in the pipeline. These are targeting egg allergy and tree nut allergy. Based on the first approval and success Aimmune had in peanut allergy treatment, it is likely